Scarica l'app Stockscreener
39.80
1.90%
-0.77
Dopo l'orario di chiusura:
39.80
Precedente Chiudi:
$40.57
Aprire:
$40.4
Volume 24 ore:
554.88K
Relative Volume:
0.63
Capitalizzazione di mercato:
$3.15B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-53.07
EPS:
-0.75
Flusso di cassa netto:
$40.13M
1 W Prestazione:
-4.53%
1M Prestazione:
-6.33%
6M Prestazione:
+57.62%
1 anno Prestazione:
-7.29%
Intervallo 1D:
$39.54
$40.58
Intervallo di 1 settimana:
$39.54
$45.55
Portata 52W:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VCYT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
39.80 | 3.21B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Underweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Hold |
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - primepublishers.com
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate - Chartmill
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT) - simplywall.st
Swing Trade: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantJuly 2025 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio - Sahm
Is Veracyte’s (VCYT) Confident Double‑Digit Revenue Outlook Altering The Investment Case For Investors? - Yahoo Finance
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating - Finviz
Centene Expands Palliative Care Access in Ohio Through Tuesday Health - Nasdaq
QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT - MarketBeat
S P Trends: Is Veracyte Inc showing insider buyingTrade Entry Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Trade Recap: Is Veracyte Inc stock a value trapJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT - MarketBeat
SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (NASDAQ:VCYT) Cut to Hold at Zacks Research - MarketBeat
Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)? - Sahm
Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT - MarketBeat
Lung Cancer Diagnostics Market Size and Forecast 2025–2033 - Vocal
Breakout Move: What is the dividend yield of CMMBJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Volume Recap: Is Veracyte Inc. stock a top pick in earnings seasonStock Surge & Accurate Trade Setup Notifications - Bộ Nội Vụ
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $44 - 富途牛牛
Morgan Stanley initiates coverage of Veracyte, Inc. (VCYT) - MSN
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook - Investing.com Australia
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook By Investing.com - Investing.com India
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement - Investing.com Nigeria
Summit Creek Advisors LLC Makes New $8.52 Million Investment in Veracyte, Inc. $VCYT - MarketBeat
Veracyte stock outlook positive as Leerink reiterates Outperform rating By Investing.com - Investing.com South Africa
Veracyte stock outlook positive as Leerink reiterates Outperform rating - Investing.com India
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results - 01net
Veracyte (VCYT) Sets Ambitious Revenue Growth Targets for 2026 - GuruFocus
Veracyte (VCYT) Poised for Growth with New Product Launches in 2 - GuruFocus
BRIEF-Veracyte Outlook FY Revenue Growth 16% - TradingView — Track All Markets
Published on: 2026-01-11 01:59:58 - ulpravda.ru
Veracyte Reports Strong Q3 2025 Financial Performance - MSN
Market Wrap: Can Veracyte Inc 12V stock reach 200 price targetJuly 2025 Final Week & Precise Buy Zone Identification - Bộ Nội Vụ
Can Veracyte Inc. (12V) stock reach $200 price targetJuly 2025 Weekly Recap & AI Driven Price Predictions - Улправда
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Veracyte Inc. stock could outperform in 2025July 2025 Decliners & Low Risk Growth Stock Ideas - Улправда
Veracyte Inc (VCYT) Stock Price Today | Live Chart & News - Traders Union
Will Veracyte Inc. stock gain from lower inflationJuly 2025 Outlook & Daily Chart Pattern Signal Reports - Улправда
Published on: 2026-01-09 02:13:40 - ulpravda.ru
Operating cash flow per share of Veracyte, Inc. – DUS:12V - TradingView — Track All Markets
Update Recap: How interest rate cuts could boost Veracyte Inc. stock2025 Analyst Calls & Technical Pattern Based Signals - Улправда
Aug Chart Watch: How interest rate cuts could boost Veracyte Inc. stockMarket Growth Report & Verified Swing Trading Watchlists - Улправда
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):